Christopher Mirabelli - Net Worth and Insider Trading

Christopher Mirabelli Net Worth

The estimated net worth of Christopher Mirabelli is at least $2 Million dollars as of 2024-11-13. Christopher Mirabelli is the CEO, President, Chairman, 10% Owner of Leap Therapeutics Inc and owns about 707,710 shares of Leap Therapeutics Inc (LPTX) stock worth over $2 Million. Christopher Mirabelli is also the Director, 10% Owner of Proteostasis Therapeutics Inc and owns about 107,465 shares of Proteostasis Therapeutics Inc (PTI) stock worth over $119,286. Details can be seen in Christopher Mirabelli's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Mirabelli has not made any transactions after 2019-02-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Christopher Mirabelli

Christopher Mirabelli Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Mirabelli owns 11 companies in total, including Leap Therapeutics Inc (LPTX) , GlobeImmune Inc (GBIM) , and Proteostasis Therapeutics Inc (PTI) among others .

Click here to see the complete history of Christopher Mirabelli’s form 4 insider trades.

Insider Ownership Summary of Christopher Mirabelli

Ticker	Comapny	Transaction Date	Type of Owner
LPTX	Leap Therapeutics Inc	2019-02-05	director & 10 percent owner & CEO,Pres,Chairman of the Board
GBIM	GlobeImmune Inc	2016-02-17	other: Former 10% Owner
PTI	Proteostasis Therapeutics Inc	2016-02-17	director & 10 percent owner
		2014-01-30	director & 10 percent owner
		2013-12-17	10 percent owner
		2011-05-17	10 percent owner
		2009-07-28	10 percent owner
		2009-10-05	10 percent owner
		2006-06-27	10 percent owner
		2016-02-10	director & 10 percent owner
		2016-02-10	director & 10 percent owner

Christopher Mirabelli Latest Holdings Summary

Christopher Mirabelli currently owns a total of 2 stocks. Among these stocks, Christopher Mirabelli owns 707,710 shares of Leap Therapeutics Inc (LPTX) as of February 5, 2019, with a value of $2 Million and a weighting of 95.07%. Christopher Mirabelli also owns 107,465 shares of Proteostasis Therapeutics Inc (PTI) as of February 17, 2016, with a value of $119,286 and a weighting of 4.93%.

Latest Holdings of Christopher Mirabelli

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
LPTX	Leap Therapeutics Inc	2019-02-05	707,710	3.25	2,300,058
PTI	Proteostasis Therapeutics Inc	2016-02-17	107,465	1.11	119,286

Holding Weightings of Christopher Mirabelli

Christopher Mirabelli Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher Mirabelli has made a total of 0 transactions in Leap Therapeutics Inc (LPTX) over the past 5 years. The most-recent trade in Leap Therapeutics Inc is the acquisition of 57,143 shares on February 5, 2019, which cost Christopher Mirabelli around $999,999.

According to the SEC Form 4 filings, Christopher Mirabelli has made a total of 0 transactions in Proteostasis Therapeutics Inc (PTI) over the past 5 years. The most-recent trade in Proteostasis Therapeutics Inc is the acquisition of 18,750 shares on February 17, 2016, which cost Christopher Mirabelli around $3 Million.

Insider Trading History of Christopher Mirabelli

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher Mirabelli Trading Performance

GuruFocus tracks the stock performance after each of Christopher Mirabelli's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher Mirabelli is 47.69%. GuruFocus also compares Christopher Mirabelli's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher Mirabelli within 3 months outperforms 3 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Christopher Mirabelli's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Christopher Mirabelli

Average Return

Average return per transaction

Outperforming Transactions

2 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	28.47
Relative Return to S&P 500(%)	24.92

Christopher Mirabelli Ownership Network

Ownership Network List of Christopher Mirabelli

No Data

Ownership Network Relation of Christopher Mirabelli

Christopher Mirabelli Owned Company Details

What does Leap Therapeutics Inc do?

Who are the key executives at Leap Therapeutics Inc?

Christopher Mirabelli is the director & 10 percent owner & CEO,Pres,Chairman of the Board of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , 10 percent owner Beigene, Ltd. , and VP & Head of Reg Affairs/Qual Christine Granfield .

Leap Therapeutics Inc (LPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Leap Therapeutics Inc Insider Transactions

No Available Data

What does GlobeImmune Inc do?

Who are the key executives at GlobeImmune Inc?

Christopher Mirabelli is the other: Former 10% Owner of GlobeImmune Inc. Other key executives at GlobeImmune Inc include other: Former 10% Owner Healthcare Ventures Vii Lp , other: Former 10% Owner John W Littlechild , and other: Former 10% Owner James H Cavanaugh .

GlobeImmune Inc (GBIM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of GlobeImmune Inc (GBIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of GlobeImmune Inc (GBIM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

GlobeImmune Inc (GBIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

GlobeImmune Inc Insider Transactions

No Available Data

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

Christopher Mirabelli is the director & 10 percent owner of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , Chief Scientific Officer Benito Munoz , and See Remarks Eric D Larson .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Trevena Inc do?

Who are the key executives at Trevena Inc?

Christopher Mirabelli is the director & 10 percent owner of Trevena Inc. Other key executives at Trevena Inc include SVP & Chief Medical Officer Mark Demitrack , SVP & Chief Business Officer Robert T Yoder , and director & President & CEO Carrie L. Bourdow .

Trevena Inc (TRVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Trevena Inc (TRVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Trevena Inc (TRVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Trevena Inc (TRVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Trevena Inc Insider Transactions

No Available Data

What does TetraLogic Pharmaceuticals Corp do?

Who are the key executives at TetraLogic Pharmaceuticals Corp?

Christopher Mirabelli is the 10 percent owner of TetraLogic Pharmaceuticals Corp. Other key executives at TetraLogic Pharmaceuticals Corp include other: See Remarks Hudson Bay Capital Management Lp , other: See Remarks Lazard Asset Management Llc , and other: See Remarks Nomura Holdings Inc .

TetraLogic Pharmaceuticals Corp (TLOG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TetraLogic Pharmaceuticals Corp (TLOG)'s detailed insider trading history can be found in Insider Trading Tracker table.

TetraLogic Pharmaceuticals Corp Insider Transactions

No Available Data

What does Radius Health Inc do?

Who are the key executives at Radius Health Inc?

Christopher Mirabelli is the 10 percent owner of Radius Health Inc. Other key executives at Radius Health Inc include director & CEO and President G. Kelly Martin , Senior Vice President Elizabeth Messersmith , and Vice President & Sales Danielle Holtschlag .

Radius Health Inc (RDUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Radius Health Inc (RDUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Radius Health Inc (RDUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Radius Health Inc (RDUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Radius Health Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Christopher Mirabelli is the 10 percent owner of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Christopher Mirabelli made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 16,011 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 16,011 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Christopher Mirabelli is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Christopher Mirabelli made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Cardiovascular Systems Inc do?

Who are the key executives at Cardiovascular Systems Inc?

Christopher Mirabelli is the 10 percent owner of Cardiovascular Systems Inc. Other key executives at Cardiovascular Systems Inc include Chief Financial Officer Jeffrey S. Points , Chief Operating Officer Rhonda J. Robb , and Chief Compliance Officer Sandra Sedo .

Cardiovascular Systems Inc (CSII) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cardiovascular Systems Inc (CSII) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cardiovascular Systems Inc (CSII) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cardiovascular Systems Inc (CSII)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cardiovascular Systems Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Christopher Mirabelli is the director & 10 percent owner of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , Chief Scientific Officer Thierry Guillaudeux , and Chief Financial Officer Keith Baker .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Christopher Mirabelli is the director & 10 percent owner of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

Over the past 18 months, Christopher Mirabelli made no insider transaction in Kineta Inc (KANT). Other recent insider transactions involving Kineta Inc (KANT) include a net purchase of 7,250 shares made by Raymond J. Bartoszek , a net purchase of 15,000 shares made by Shawn Iadonato , and a net purchase of 10,000 shares made by Keith Baker .

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 50,250 shares were bought by its insiders, resulting in a net purchase of 50,250 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

Christopher Mirabelli Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Mirabelli. You might contact Christopher Mirabelli via mailing address: 55 Cambridge Parkway, Suite 301, Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.